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Background: The cell microenvironment, especially extracellular matrix proteins, plays an important role in tumor
cell response to chemotherapeutic drugs. The present study was designed to investigate whether this
microenvironment can influence the antimigratory effect of an anthracycline drug, doxorubicin, when tumor cells
are grown in a matrix of type I collagen, a three-dimensional (3D) context which simulates a natural
microenvironment.
Methods: To this purpose, we studied the migratory parameters, the integrin expression, and the activation state
of focal adhesion kinase (FAK) and GTPase RhoA involved in the formation of focal adhesions and cell movement.
These parameters were evaluated at non toxic concentrations which did not affect HT1080 cell proliferation.
Results: We show that while doxorubicin decreased cell migration properties by 70% in conventional two-
dimensional (2D) culture, this effect was completely abolished in a 3D one. Regarding the impact of doxorubicin
on the focal adhesion complexes, unlike in 2D systems, the data indicated that the drug neither affected b1
integrin expression nor the state of phosphorylation of FAK and RhoA.
Conclusion: This study suggests the lack of antiinvasive effect of doxorubicin in a 3D environment which is
generally considered to better mimic the phenotypic behaviour of cells in vivo. Consistent with the previously
shown resistance to the cytotoxic effect in a 3D context, our results highlight the importance of the matrix
configuration on the tumor cell response to antiinvasive drugs.
Background
Cancer metastases are particularly challenging for the
medical field and represent a major hurdle in cancer
chemotherapy of solid neoplasia. This process confers
poor prognosis for the affected patient. In fact, it is gen-
erally considered that 90% of human cancer deaths can
be attributed to local invasion and/or distant metastases
[1]. Given the fact that most current chemotherapeutic
protocols aim at direct inhibition of tumor cell growth,
the development of antimetastatic agents could be an
effective means to prevent colonization, thereby
enabling the containment of primary tumors in a che-
mically manageable form [2]. In the search of antitumor
agents with anti-invasive properties, evidence has
recently accumulated indicating that anthracyclines, one
of the most potent classes of chemotherapeutic agents
in clinical use, inhibit tumor cell invasion [3]. Indeed,
doxorubicin [4,5] and related compounds such as aclaci-
nomycin [6], or DA-125, a doxorubicin analogue [7],
have been shown to inhibit in vitro invasion of various
tumor cell lines originating from solid tumors when
used at low concentrations. The underlying mechanism
deals with either downregulation of matrix metallopro-
teinases [7] or disorganization of cytoskeleton and focal
contacts [8].
One of the limitations of such studies is that they
were performed on conventional tissue culture substrate,
as i t u a t i o nt h a td o e sn o tt a k ei n t oa c c o u n tt h et u m o r
cell microenvironment in which tumor cells in vivo
exert complex interactions with their immediate neigh-
bors and the extracellular matrix (ECM). For this rea-
son, it is of primary importance in the search of cell
invasion inhibitors to consider the tumor cell
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Indeed, it has been demonstrated as a key determinant
of cell response to anticancer drugs; this, being due to
multiple mechanisms including limited drug penetration,
tumor cell adaptation to hypoxia, presence of an acidic
extracellular pH and direct contact between cancer cells
and the extracellular matrix or adjacent cells that induce
cell-mediated adhesion resistance [9]. In vivo,s u c h
environmental causes have been suspected to contribute
to cancer cell survival after initial therapy, allowing
resistant cells to proliferate.
To evaluate the impact of microenvironment on the
drug response, different types of matrices have been
studied such as classical two-dimensional (2D)
matrices or more recently fibroblast-derived three-
dimensional (3D) matrices [10,11]. Studies have mainly
focused on the cytotoxic or proapoptotic effects
induced by an extensive panel of well-known che-
motherapeutics either microtubule-disturbing agents
such as vinca-alcaloids, taxoids or DNA-damaging
compounds such as nitrogen mustards and anthracy-
clines [12,13]. It has been shown that epithelial and
leukemic cell lines when grown onto such matrices
may respond differently to these drugs and in some
cases acquire cell mediated-adhesion resistance [10]. In
accordance to this, we recently reported such a micro-
environment-dependent resistance for the anti-invasive
effect of anthracyclines. Indeed by contrast to plastic,
human fibrosarcoma cells cultured on 2D surfaces
coated with ECM proteins collagen type I and fibro-
nectin were not affected by the antimigratory effect of
doxorubicin [4]. Compared to evaluation of drug
responsiveness of cells cultured on 2D coatings or
onto 3D matrices, culturing cells within 3D matrices
offers both a more realistic view due to the coupling of
chemical and mechanical signals that takes place in the
real tissues and better simulates cell response to anti-
tumor drugs [14]. Since ECM appears as an important
regulator of tumor cell response to chemotherapeutics
and since nothing is known about the anti-invasive
effects of anthracyclines in a 3D context, this study
was designed to investigate whether the cell microen-
vironment can influence the antimigratory effect of the
anti-tumor drug doxorubicin when human fibrosar-
coma HT1080 cells are grown in a 3D collagen type I
matrix. To this purpose, the current study examined
migratory parameters by time-lapse videomicroscopy,
the actin cytoskeleton organisation and the integrin
expression. The activation state of FAK [15] and
GTPase RhoA [16], two proteins involved in the for-
mation of focal adhesion complexes and cell move-
ment were also investigated. The data show that this
3D context protects the tumor cells against the antimi-
gratory effect of non cytotoxic doses of doxorubicin.
Results
Determination of doxorubicin subtoxic concentrations in
3D cultures
To rule out a putative direct cytotoxic impact of the
drug on cell migration, the ability of doxorubicin to
decrease tumor cell motility was investigated at concen-
trations exhibiting no or limited effect on tumor cell
proliferation. To this end, the effect of increasing con-
centrations of doxorubicin (up to 10 nM) on HT1080
cell growth was determined on cells either cultured in
3D collagen type I matrices or cultured on 2D plastic
substrata. Figure 1 indicates that doxorubicin at 2.5 and
5 nM inhibited 3D cell proliferation by less than 10%
when compared with the control. By contrast, for 7.5
and 10 nM, cells experienced a significant increase in
antiproliferative effect by 28% and 43%, respectively. On
2D plastic, although more marked growth inhibitory
effects were observed for the same drug concentrations,
this inhibition remained limited for 2.5 and 5 nM which
inhibited cell growth by 12 and 25% respectively. For
both types of culture, cell viability was not affected. Tak-
ing into account these results, the impact of doxorubicin
on 3D cell migration was studied in all further experi-
ments at concentrations of 2.5 and 5 nM, which did not
significantly influence cell proliferation, and at 7.5 nM
as representative of a moderate cytostatic effect.
Evaluation of the antimigratory effect of doxorubicin in
3D
The migration ability of HT1080 cells cultured within
collagen type I matrices has been determined by quanti-
fying their migration speed and their 3D trajectories
using computer-assisted videomicroscopy. To this end,
Figure 1 Antiproliferative effect of doxorubicin in HT1080 cells
cultured within 3D matrix. After 48 h of culture in 3D matrix or
on 2D plastic, cells were treated with doxorubicin at 0, 2.5, 5, 7.5 or
10 nM for 24 h. Then, cells were counted to evaluate cell number.
Values represent the mean ± S.E.M. of three independent
experiments.
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vidual cells were examined for their migrating potential
between 12 h and 24 h after incubation with the drug.
As previously shown on 2D plastic [4], doxorubicin
induced a significant antimigratory effect at the non
cytotoxic doses of 2.5 and 5 nM (Figure 2). Indeed, trea-
ted cells exhibited a median speed of 5 μm/h compared
to 18 μm/h in control cells, indicating that the drug
inhibited cell migration by about 70%. By contrast, for
t h es a m ed r u gc o n c e n t r a t i o n s ,t h e3 Dc o l l a g e nt y p eI
matrix totally abolished this drug antimigratory effect
since the median speed of treated cells (23 μm/h) is
similar to that of control cells (25 μm/h). This 3D col-
lagen protective effect was also observed for the low
cytostatic concentration of 7.5 nM. In addition to the
estimation of the migration speed, continuous single cell
tracking permitted the investigation of trajectories of
cells grown in both models and treated or not with dox-
orubicin 5 nM (Figure 3). In 2D, whereas control cells
moved along linear paths, treated cells exhibited circular
trajectories around their starting point, in accordance
with cell migration speed inhibition. By contrast, in 3D,
the trajectories of treated cells appeared similar to that
of control cells, which is in agreement with the protec-
tive effect of collagen on cell migration speed. Taken
together, our data indicate that the 3D collagen type I
matrix protects tumor cells against the antimigratory
effect of doxorubicin.
Cell phenotype in 3D and impact of doxorubicin
Inside the cell matrix, HT1080 cells adopted a morphol-
ogy dramatically distinct from the one observed in cells
growing on planar substrata as shown by phase contrast
microscopy and localization of F-actin (Figure 4). In 2D,
cells develop a flattened morphology with a classical
tear-drop shape displaying a wide leading edge and a
narrow tail (Figure 4A). By contrast, cells in 3D matrices
demonstrate extremely elongated cell bodies with a far
more compacted nucleus which can be bipolar or stel-
late (Figure 4B). Cylindrical branched pseudopodia
structures are also observed during active phases of
migration when cells explore the microenvironment to
find paths between the collagen fibrils (additional files 1
and 2). Compared to 2D, where cells exhibit a dense
and regular actin stress fiber network (Figure 4C, addi-
tional files 3 and 4), in 3D models cells show some actin
bundles in the cell body continuing into pseudopodia;
actin patches were also found near the cell membrane
(Figure 4D, additional files 5 and 6). In addition, there
was no significant difference in the total amount of
actin present between 3D and 2D grown cells (74 ± 12
arbitrary units/cell in 3D vs 87 ± 11 arbitrary units/cell
in 2D, n = 10 cells). In 2D, treatment with 5 nM doxor-
ubicin induces a loss of cell polarity and a dramatic dis-
organization of the stress fibers (Figure 4E, additional
files 7 and 8) whereas in 3D, cell morphology and actin
distribution were similar to that of control cells (Figure
4F, additional files 9 and 10). These results clearly
demonstrate that in 3D, non toxic concentrations of
doxorubicin have no effect on cytoskeleton integrity
which is consistent with the collagen protective effect
on cell parameters.
Effect of doxorubicin on migration molecular regulators
in 3D
Since in 2D tumor cell motility is strongly dependent on
the expression and functioning of integrins, FAK [15]
and RhoA [16], these proteins were analyzed in 3D after
drug treatment. As shown by flow cytometry (Figure 5),
expression of b1 integrins, which are representative of
the integrins expressed in HT1080 cells, was found to
be unaffected by doxorubicin at 2.5 and 7.5 nM in 3D.
Similar results were obtained with the same concentra-
tions of drug in 2D culture suggesting that doxorubicin
does not affect the expression level of integrins in pre-
sence or not of matrix proteins. In addition, it has to be
noticed that in 3D culture the level of b1i n t e g r i n
expression is 3-fold lower than in 2D culture. This
decrease takes place during the first 10 hours of 3D cul-
ture and is in agreement with the dramatic morphologi-
cal changes observed in 3D cells (Figure 6). Figure 7
depicts the western blot analysis of FAK (Figure 7A)
and RhoA (Figure 7B) in 3D cultures treated or not
Figure 2 E f f e c to fd o x o r u b i c i no n3 DH T 1 0 8 0c e l lm i g r a t i o n
speed. Cells cultured during 48 h within 3D matrix or on 2D plastic
were incubated with doxorubicin at 0, 2.5, 5 and 7.5 nM for 24 h
and were tracked by time-lapse videomicroscopy during the last 12
h of drug incubation. The migration speed was displayed as a box
plots (bottom of box, 25th percentile; and top of box, 75th
percentile) and middle line indicates the median (15 cells per
sample). *** p < 0.001 significant difference between control and
doxorubicin treatment.
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that neither expression nor activation of these two pro-
teins was influenced by the drug. These results strongly
contrast with those obtained in 2D plastic cultures
where the drug dramatically decreases the activation
state of FAK and RhoA [4].
Discussion
We demonstrate here that 3D type I collagen matrix
protects human fibrosarcoma cells against the antimi-
gratory effect of subtoxic concentrations of the antitu-
mor drug doxorubicin. To our knowledge, this is the
first study to show that ECM proteins in a 3D config-
uration are able to protect cancer cells from the antimi-
gratory effect of a drug. This protective effect can be
assimilated to a new form of environment-mediated
drug resistance recently described for the cytotoxic
effect of various antitumor drugs [9].
The effect of doxorubicin on tumor cell migration
was studied here at concentrations moderately affect-
ing or not cell proliferation in order to exclude the
possibility that its antimigratory effect could result
from a non specific consequence of the cytotoxic effect
of this drug. Moreover, this is of considerable interest
since the use of doxorubicin is often limited by severe
cardiotoxicity and other undesirable side effects [17].
The 3D culture system used here is a 3D gel of type I
collagen, which corresponds to a representative model
that mimicks in vivo microenvironment. Type I col-
lagen is a main component of extracellular matrix in
the body connective tissues, through which tumor cells
usually move to form metastases, and use as a pre-
intravasation microenvironment [10]. The 3D collagen
gel prepared here at physiological concentration [18]
approximates the 3D fibrous nature of a mesenchymal
stroma by displaying a highly fibrillar organization as
shown previously [19]. In addition, due to its prepara-
tion without pepsinization, this native fibrillar collagen
presents intact telopeptides in contrast with most of
the experimentally generatedc o l l a g e nm a t r i c e sc u r -
rently using pepsin-cleaved collagen type I [20]. Telo-
peptides which correspond to the flanking regions of
the molecules permit to form intra- and intermolecular
cross-links that promote the staggering and the resili-
ence of fibrillar collagen [21]. Such a 3D culture model
has previously been shown not to affect doxorubicin
penetration both in the gel and the tumor cells, indi-
cating that the subtoxic concentrations defined in 2D
can be easily transposed to 3D conditions. Indeed, by
using quantitative microspectrofluorimetry, it has been
shown that doxorubicin rapidly diffuses through the
3D collagen gel so that, after 1 h of incubation, drug
concentrations are similar in the 3D matrix and the
medium covering the gel. In addition, the intracellular
Figure 3 Quantitative analysis of 3D trajectories on doxorubicin-treated HT1080 cells. Cells cultured during 48 h within 3D matrix or on
2D plastic were incubated with doxorubicin 0 and 5 nM for 24 h and were tracked by videomicroscopy during the last 12 h of drug incubation.
Each colour on the figure corresponds to different cells (15 cells per sample). (Bar = 100 μm).
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type I collagen matrix or on 2D substrata were incubated with doxorubicin 0 and 5 nM for 24 h. Typical morphology of cells seeded on 2D
substrata (A) or cultured within 3D matrix (B) were obtained by phase contrast microscopy. F-actin was stained by immunofluorescence with
Alexa Fluor 488 phalloidin and captured using confocal microscopy in control cells in 2D (C)o r3 D( D), and in treated cells in 2D (E)o r3 D( F).
(Bar = 5 μm).
Figure 5 Effect of doxorubicin on b1 integrin expression in 3D
HT1080 cells. Cells cultured during 48 h within 3D type I collagen
matrix or on 2D substrata were incubated with doxorubicin 0 and 5
nM for 24 h. Then, they were stained with total-b1 integrin
monoclonal antibody and analyzed by flow cytometry. Data shown
are representative of three independent experiments.
Figure 6 Differential expression of b1 integrins in 2D and 3D
HT1080 cells. Cells were cultured in 3D collagen gel or on 2D
substrata and flow cytometric analysis of b1 integrins was
performed up to 72 hours. Data shown are representative of three
independent experiments.
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compared to 2D conditions [19].
The behaviour of HT1080 cells cultured in the 3D
matrices appears dramatically different from that of cells
cultured on rigid and planar 2D substrata. Indeed, on
2D, cells exhibit the classical tear-drop morphology with
a flat cross-section and a broad lamellipodium. On the
other hand, in 3D, they adopt a bipolar, spindle or stel-
late shape, and express a lower level of b1 integrins
which can be explained by the marked decrease of their
cell volume as estimated by flow cytometry (data not
shown). The observed cell protrusions constituted of
thin and cylindric dendritic extensions are in favour of a
mesenchymal migration mode [22]. As recently pro-
posed [19], and as shown in our videomicroscopy
sequences, these protrusions may sense the surrounding
matrix and those that extend in a favourable direction
then guide cell movement. Whereas HT1080 cells
migrating across 2D plastic surfaces present classical
actin stress fibers, those moving through 3D collagen
lack actin stress fibers but exhibit a cortical cytoskeleton
and actin-rich tips in their dendritic extensions. Such
structural changes are similar to those observed for
human foreskin fibroblasts seeded on top of relaxed
type I collagen matrices [23] and appeared to be a char-
acteristic of the cell-collagen matrix interface. This high
degree of plasticity in cell shape and actin organization
m a yb ep a r t i c u l a r l yf a v o u r a b l ed u r i n gt h em e t a s t a s i s
process and may contribute to the high invasiveness
potential of this cell line in animal models [24].
Cell migration speed and individual trajectories were
determined using time-lapse videomicroscopy and inter-
active cell tracking in a four-dimensional data set [25].
It is demonstrated that cell migration speed is higher in
3D compared to plastic substrate (25 μm/h versus 18
μm/h, p < 0.01 data not shown). In 2D, doxorubicin
markedly slows down cell locomotion by decreasing cell
migration speed by about 70% and by disorganizing
actin cytoskeleton. Our data are in accordance with pre-
vious studies demonstrating that other derivatives of
anthracycline drugs, such as aclacinomycin [6] or DA-
125 [7], also exhibited a significant antimigratory effect
on plastic. Surprisingly, in 3D collagen matrix, this anti-
migratory effect was completely abolished as proved by
the absence of drug impact on cell migration speed and
cytoskeleton organization. The fact that the global con-
tent of actin is roughly the same in 2D and 3D grown
cells, rules out the assumption that doxorubicin has no
pharmacological target (i.e., actin), thus no impact in 3D
culture. Such data are completely in agreement with the
inhibitory effect of ECM components on the cytotoxic
mechanism of various antitumor drugs [26]. This was
Figure 7 Effect of doxorubicin on FAK and RhoA expression in 3D HT1080 cells. Cells were cultured during 48 h in 3D collagen gel then
treated with 2.5, 5 or 7.5 nM of doxorubicin for 24 h. Representative immunoblot of total FAK or Tyr
397-FAK (A) and of total RhoA and RhoA-
GTP (B). The graphs show the mean values of three independent experiments.
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poietic or solid tumors. Indeed, these cells are protected
from drug-induced apoptosis when cells were plated on
ECM proteins such as fibronectin, laminin-1 and col-
lagens [27]. In addition, our results also show that the
activation of both FAK and GTPase RhoA, key regulator
enzymes of cell motility, that markedly decreased in 2D
by doxorubicin [4], is unaffected in 3D. These data are
in agreement with the recent demonstration that biop-
sies of doxorubicin-treated breast cancer patients, exhib-
ited upregulation of genes involved in the focal adhesion
pathway [28]. In vivo, ECM proteins such as collagen
type I may conceivably impair the pharmacological
properties of anthracyclines, triggering an intrinsic che-
motherapeutic resistance. In addition, the development
of selective inhibitors of FAK is proposed as a promising
way of inhibiting migration and invasion [29]; the pre-
sent results provide substantial evidence that the micro-
environment parameter has to be considered to isolate
such inhibitors.
Conclusion
Our data clearly demonstrate that ECM proteins inhibit
the antimigratory effect of the antitumor drug doxorubi-
cin. They support the crucial role of the tumor environ-
ment in the failure of clinical response to
chemotherapeutic agents and the emergence of an
environment-mediated drug resistance. This experimen-
tal approach should be taken into account for a better
definition of robust in vitro drug screening tests, this in
order to find new agents specifically targeting the in
vivo migrating behaviour of tumor cells.
Methods
Cell line
The human fibrosarcoma HT1080 cells (CCL-121) were
purchased from the American Type Culture Collection
(ATCC, Rockville, USA) and cultured in MEM with
Earle salts and Glutamax I (Invitrogen, Cergy-Pontoise,
France) supplemented with 10% fetal bovine serum
(FBS) (Invitrogen). Cultures were maintained at 37°C in
a humidified atmosphere containing 5% (v/v) CO2.C e l l s
were routinely passaged at preconfluency using 0.05%
trypsin-0.53 mM EDTA (Invitrogen) and screened for
the detection of mycoplasma using PCR methods.
3D culture and drug treatment
Acid-extracted, non-pepsinized collagen type I from rat
tail tendons was prepared as already described [30]. Lyo-
philized collagen was dissolved in sterile 18 mM acetic
acid at a concentration of 3 mg/ml. To prepare 3D cul-
tures, 5 × 10
4 HT1080 cells were resuspended in 50 μL
FBS and mixed with a solution containing 50 μlM E M
10× (Sigma-Aldrich, L’Isle d’Abeau Chenes, France), 50
μlN a H C O 3 0.26 M, 50 μlH 2O, 45 μlN a O H0 . 1M ,5
μl glutamine 200 mM and 250 μlc o l l a g e n3m g / m l .
This solution was deposited in 24-well plates (500 μl/
well). After polymerization at 37°C during 10 min, gels
were recovered by 500 μl MEM 10% foetal calf serum
and 3D cultures were incubated during 48 h before drug
treatment. Then, medium recovering 3D cultures was
replaced by 500 μl of fresh complete culture medium
containing or not 2-fold concentrations of doxorubicin
(TEVA Pharma S.A., Courbevoie, France). After 24 h,
gels were digested by collagenase P at 1 mg/ml (Roche,
Meylan, France), cell viability and cell number were
determined by phase contrast microscopy. In parallel,
conventional 2D cultures were performed by seeding
HT1080 cells in 24-well plates at a concentration of 2 ×
10
4 cells/ml (1 ml/well). After 48 h, culture medium was
removed and cells were exposed to the doxorubicin
treatment for 24 h.
3D cell migration quantification and actin staining
3D and 2D cultures, prepared as described above, were
seeded in 12-well plates (2 ml/well). Cell motility was
analyzed by time-lapse videomicroscopy using an
inverted microscope Axiovert 200 M (Zeiss, Le Pecq,
France) equipped with a small transparent environmen-
tal chamber Climabox (Zeiss) with 5% (v/v) CO2 in air
at 37°C. The microscope was driven by the Metamorph
software (Roper Scientific, Evry, France) and images
were recorded with a charge-coupled device camera
CoolsnapHQ (Roper scientific). Cell migration was
quantified using an interactive tracking method as pre-
viously described [25]. For actin staining, after 24 h of
incubation in presence of drug, cells were fixed using
4% paraformaldehyde in PBS for 1 h at room tempera-
ture. Cells were permeabilized with 0.5% Triton X-100
in PBS for 5 min. Samples were blocked with PBS con-
taining 3% BSA with 0.3% Triton X-100 for 45 min. F-
actin was detected using Alexa Fluor 488 Phalloidin
(1:500, Invitrogen). Fluorescence images were captured
using the confocal laser scanning microscope Zeiss LSM
710 (Zeiss). The actin content of the cells was quanti-
tated by measuring the pixel fluorescence intensity using
the ImageJ software [31].
Flow cytometry of b1 integrins
After collagenase P treatment of 3D cultures or trypsi-
nation of 2D cultures, cells were incubated at room
temperature for 45 min with PBS containing 10 μla n t i -
bodies against integrin subunits b1 coupled with FITC
(Beckman Coulter, Villepinte, France) or 50 μlm o u s e
IgG1-FITC as negative control (Beckman Coulter). Cells
were then washed in PBS (pH 7.2) and assessed for
fluorescence in a FACSCalibur flow cytometer (BD Bios-
ciences, Le Pont de Claix, France).
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After collagenase P treatment, cells were lyzed with
extraction buffer (Tris 10 mM pH 7.5, NaCl 150 mM,
1% (v/v) Triton X-100, 5% (v/v) PMSF 100 mM, 20% (v/
v) NEM 30 mM, 20% (v/v) SDS 10%). Cell lysates were
clarified by centrifugation at 10,000 g at 4°C for 10 min.
Briefly, proteins were separated by 7% SDS-PAGE gels
and transferred to a PVDF membrane. Then membranes
were blocked with Tris-buffered saline (TBS) (20 mM
Tris-HCl, pH 7.4, 137 mM NaCl) containing 0.1% tween
(TBS-T) and 5% non-fat dry milk at room temperature
during 1 h and incubated overnight at 4°C with either
rabbit polyclonal antibodies raised against total FAK
(1:5000, Millipore, Saint-Quentin en Yvelines, France) or
[Y397] phosphorylated-FAK (1:1000, Millipore). Mem-
branes were washed with TBS-T and incubated with
peroxidase-conjugated anti-mouse IgG (1:20000, Milli-
pore) at room temperature during 1 h. Chemilumines-




To assess RhoA activation, the amount of RhoA-GTP
bound to the Rhotekin RBD was determined using the
Rho Activation Assay Kit (Cytoskeleton, Denver, USA)
according to the manufacturer’s instructions. Briefly,
after collagenase P treatment of 3D cultures, cells were
lyzed using the lysis buffer from the kit. Proteins were
incubated with RBD-rhotekin beads for 60 min at 4°C.
Beads were washed three times with wash buffer, resus-
pended in Laemmli sample buffer, and boiled for 2 min.
Separation by 12% SDS-PAGE, transfer and blocking
were processed as the FAK activation assay. Proteins
were immunoblotted with anti-RhoA antibodies (1:500)
and chemiluminescent detection was realized by using
an ECL
+ kit (GE Healthcare).
Statistical analysis
Data are presented as mean ± SEM except for migration
speed which displayed as box-blot ranging from the 25th
to 75th percentile including the median and whiskers
from the 5th to 95th percentile. The values were analyzed
with Kruskall-Wallis followed by Mann-Whitney test.
Statistical significance was set at p < 0.05.
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